Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Summary

This phase II clinical trial studies the side effects and how well imatinib mesylate works in treating patients with uterine cancer that has failed to respond to initial chemotherapy or has re-grown after therapy. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2004-01

Primary completion

2010-07

Completion

2010-07

Drugs

Indications